/

IMCR

Immunocore Holdings plcAfter hours

27.82−1.22 −4.20%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 27.82 0.00%

Open

29.00

Prev close

29.04

Day range

27.6529.25

52-week range

27.5640.72

Volume

904.45K2.09×

Mkt cap

1.43B

P/E ttm

—

Fwd P/E

-36.88

EPS ttm

-0.3600

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−31.67%

Price Chart

Yahoo Finance · delayed

IMCROct 13, 2026O 29.00H 29.25L 27.65C 27.82−1.22 (−4.20%)Vol 904.45K

SMA 5033.33
SMA 20031.94

1Y change −14.14% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IMCR Immunocore Holdings plc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.85%
1 month: −14.66%
3 months: −16.88%
6 months: −12.21%
Year to date: −19.85%
1 year: −14.00%

Valuation & ownership

Market cap: 1.43B
Enterprise value: 1.05B
P/E (ttm): —
Forward P/E: -36.88
PEG ratio: —
Price / book: 3.41
Price / sales (ttm): 3.33
EV / EBITDA: 1389.24
EPS (ttm): -0.3600
EPS (forward): -0.7544
Beta (5y monthly): 0.81
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 51.50M
Float: 45.83M
Short % of float: 17.05%
Short ratio (days): 20.72
Held by insiders: 0.07%
Held by institutions: 103.18%
Avg volume (3m): 433.56K
50-day average: 33.42
200-day average: 31.98
52-week change: −14.00%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 22.3
vs 50-day SMA: −16.53%
vs 200-day SMA: −12.90%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.03%
Realised vol (20d, ann.): 24.3%
From 52-week high: −31.67%
From 52-week low: +0.96%

ANR

Analyst Consensus

11 analysts

Consensus

Buy

1.77 on a 1 (strong buy) – 5 (sell) scale

Mean target

62.73

+125.48% implied

Low 34.00Median 60.00High 100.00

Recommendation trend

Now9 / 4 / 0
1m ago / 4 /

DES

About Immunocore Holdings plc

Yahoo Finance profile

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Sector: Healthcare
Industry: Biotechnology
Employees: 524
Headquarters: Abingdon, United Kingdom
Website: immunocore.com
Officers: Dr. Bahija Jallal Ph.D.

SEAS

Seasonality · IMCR

2021–2026 · monthly returns

Strongest month Nov +9.54%Weakest month Feb −7.56%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-6.2	-0.8	-6.7	-7.4	3.5	9.9	6.5	7.4	-16.6	-8.2			−19.9%
2025	11.5	-10.7	1.0	1.4	21.6	-14.3	4.4	-1.7	12.8	-8.9	19.4	-12.1	+17.7%
2024	5.8	-7.0	-3.3	-9.1	-17.1	-30.8	17.1	-9.6	-13.2	-1.0	6.2	-9.9	−56.8%
2023	7.4	-10.5	-9.9	17.4	-4.9	8.7	10.0	-14.7	-7.8	-14.5	18.8	29.6	+19.7%
2022	-34.1	-2.1	35.3	9.1	-13.1	31.6	23.7	14.5	-11.1	21.7	9.9	-9.1	+66.7%
2021			-12.0	-5.2	1.6	-4.8	-16.2	5.6	7.3	3.9	-6.6	-4.9	−29.2%

INSD

Insider Activity · IMCR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Feb 17, 2026	Jallal BahijaChief Executive Officer	Sale at price 32.35 per share.	11.5K	$371.18K
Feb 17, 2026	Goll John ROfficer	Sale at price 32.35 per share.	698	$22.58K
Feb 17, 2026	Berman David MOfficer	Sale at price 32.35 per share.	6K	$192.97K
Feb 17, 2026	St Leger Tina AmberOfficer	Sale at price 32.35 per share.	1K	$32.35K
Feb 16, 2026	Jallal BahijaChief Executive Officer	—	23.8K	—
Feb 16, 2026	Goll John ROfficer	—	1.4K	—
Feb 16, 2026	Berman David MOfficer	—	11.8K	—
Feb 16, 2026	St Leger Tina AmberOfficer	—	2.1K	—
Dec 3, 2025	Berman David MOfficer	Conversion of Exercise of derivative security at price 40.22 per share.	31.3K	$1.26M
Nov 27, 2025	Berman David MOfficer	Conversion of Exercise of derivative security at price 17.46 per share.	74.9K	$1.31M
Nov 27, 2025	Berman David MOfficer	Sale at price 40.09 - 40.12 per share.	74.9K	$3.01M
Nov 24, 2025	Berman David MOfficer	Conversion of Exercise of derivative security at price 17.46 per share.	18.1K	$316.38K
Nov 24, 2025	Berman David MOfficer	Sale at price 40.00 - 40.03 per share.	18.1K	$725.34K
Sep 11, 2025	Berman David MOfficer	Conversion of Exercise of derivative security at price 35.24 per share.	22.5K	$794.03K
Sep 10, 2025	Berman David MOfficer	Conversion of Exercise of derivative security at price 17.46 per share.	50.4K	$880.32K
Sep 10, 2025	Berman David MOfficer	Sale at price 36.12 - 36.77 per share.	50.4K	$1.82M
Mar 16, 2025	Baker Bros Advisors L.P.Director	Purchase at price 29.56 - 29.74 per share.	807.3K	$23.99M

13F

Investors Holding IMCR

latest 13F filings of 29 followed managers

Investors holding IMCR
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$3.3M	0.00%	102.40K	−38%	Q2 2026
Bridgewater Associates · Ray Dalio	$1.2M	0.00%	36.71K	+94%	Q2 2026
Oaktree Capital · Howard Marks	$766.4K	0.01%	833.00K	—	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

IMCR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IMCR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Immunocore Holdings plc

Seasonality · IMCR

Insider Activity · IMCR

Congress Trades · IMCR

Investors Holding IMCR

Investors Holding IMCR

Congress Trades · IMCR

Insider Activity · IMCR

Seasonality · IMCR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Immunocore Holdings plc

Financial Snapshot

Earnings & Dividends

News